Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for BiOptic Inc. (6850:TWSE), powered by AI.
BiOptic Inc. is currently trading at $34.30. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for BiOptic Inc. on Alpha Lenz.
BiOptic Inc.'s P/E ratio is 49.7.
“BiOptic Inc. trades at a P/E of 49.7 (premium valuation) with modest ROE of 5.2%.”
Ask for details →BiOptic Inc. is a biotechnology instrumentation company specializing in the development and manufacturing of advanced scientific instruments for research and clinical diagnostics. Since its founding in 2004, the firm has focused on innovative solutions utilizing Capillary Gel Electrophoresis (CGE) technology, enabling precise analysis of DNA, RNA, and proteins for laboratories worldwide. Its product portfolio includes bio-fragment analyzers, PCR thermal cyclers, disposable gel cartridges for nucleic acid and protein analysis, and specialized quantification kits and reagents. BiOptic's instruments are designed to support applications across life science research, clinical diagnostics, pharmaceutical development, food safety, and agricultural testing. The company operates global support centers and maintains strong collaborations with universities, research institutes, and industrial partners, ensuring rigorous quality standards (ISO 13485 certified) and broad international reach. BiOptic Inc. plays a key role in advancing molecular diagnostics and biotechnology research by offering reliable, cost-effective solutions for academic, governmental, and commercial laboratories in over 50 countries.
“BiOptic Inc. trades at a P/E of 49.7 (premium valuation) with modest ROE of 5.2%.”
Ask for details →BiOptic Inc. (ticker: 6850) is a company listed on TWSE in the Healthcare sector (Biotechnology). Market cap is $1.1B.
The current price is 34.3 with a P/E ratio of 49.71x and P/B of 2.51x.
ROE is 5.16% and operating margin is 9.46%. Annual revenue is $203M.